Emergent BioSolutions Receives U.S. FDA Approval on Supplemental New Drug Application for NARCAN® Nasal Spray to be Packaged in a New Carrying Case, Making Life-Saving Naloxone More Accessible for Everyday Preparedness

Emergent BioSolutions (NYSE:EBS) announced FDA approval of a supplemental NDA to package OTC NARCAN® Nasal Spray in a new compact carrying case that holds two blister-packed doses with a Quick Start Guide.

Rhea-AI Summary

Emergent BioSolutions (NYSE:EBS) announced FDA approval of a supplemental NDA to package OTC NARCAN® Nasal Spray in a new compact carrying case that holds two blister-packed doses with a Quick Start Guide. The case is designed for discretion and daily carry to improve readiness during opioid emergencies. Company survey data cited 74% overall and 81% among college students preferring a discreet carrying case. The release notes only 10% of consumers currently carry naloxone. The carrying case will be available soon at select retailers, online, and via NARCANDirect. Since 2016, the company reports > 85 million doses distributed in the U.S. and Canada.

Positive

• FDA approval for sNDA enabling new OTC carrying case
• Carrying case contains two blister‑packed doses with Quick Start Guide
• Company survey: 74% consumer preference for discreet carrying case
• Reported > 85 million NARCAN doses distributed since 2016

Negative

• Only 10% of general consumers currently carry naloxone
• Initial availability limited to select retailers and online

Argus Jan 14 session

+3.04% close to close Open Argus

Details

News Market Reaction – EBS

In the Jan 14 session, EBS gained 3.04%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details U.S. FDA approval for packaging OTC NARCAN Nasal Spray in a new carrying c...

Analysis

This announcement details U.S. FDA approval for packaging OTC NARCAN Nasal Spray in a new carrying case holding two doses, aimed at improving discretion and everyday carry. Survey data show strong preference for such designs, yet actual carry rates remain low. In recent months, Emergent has combined regulatory wins with debt reduction efforts and government contracts. Observers may track uptake of the new format, future NARCAN-related updates, and additional regulatory or contract milestones to gauge strategic progress.

Key Figures

Consumer preference: 74% College student preference: 81% Everyday carry rate: 10% +4 more

Consumer preference

74%

Consumers preferring discreet carrying case over standard packaging

College student preference

81%

College students preferring discreet carrying case

Everyday carry rate

10%

General consumer population carrying naloxone

Carrying case doses

2 doses

Two doses of NARCAN Nasal Spray per carrying case

Blister packs

2 blister packs

Two blister packs in new carrying case packaging

Doses distributed

85 million

NARCAN Nasal Spray doses distributed in U.S. and Canada since 2016

Prescription launch year

2016

Year of U.S. prescription launch of NARCAN Nasal Spray

Historical Context

5 past events · Latest: Jan 12

5 events

1. Jan 12

   Debt reduction

   24h Move

   -4.4%

   Voluntary prepayment of $100M term loan, reducing gross debt materially.

2. Jan 08

   Government contract

   24h Move

   -3.0%

   Delivery order up to $21.5M for BioThrax supply in 2026–2028.

3. Jan 08

   Clinical collaboration

   24h Move

   -3.9%

   Support for Africa CDC MpOx study with clean safety review in 50 patients.

4. Jan 07

   Conference presentation

   24h Move

   +5.7%

   J.P. Morgan Healthcare Conference presentation announcement with webcast access.

5. Dec 12

   FDA manufacturing nod

   24h Move

   -2.6%

   FDA approval to add Winnipeg site for raxibacumab manufacturing and testing.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

supplemental new drug application, over-the-counter, naloxone, opioid overdose, +1 more

5 terms

supplemental new drug application regulatory

"FDA has approved its supplemental New Drug Application (sNDA) for over-the-counter..."

A supplemental new drug application is a request submitted to regulatory authorities to make changes to an existing approved medication, such as adding new uses, strengths, or formulations. For investors, it signals that a pharmaceutical company is seeking approval for new product developments or expanded applications, which can impact the company's future sales, market potential, and stock value.

over-the-counter regulatory

"approved its supplemental New Drug Application (sNDA) for over-the-counter (OTC) NARCAN..."

Over-the-counter describes securities or trades that occur directly between buyers and sellers rather than on a formal stock exchange. Think of it like buying at a flea market instead of a big supermarket: prices, rules and transparency can vary, which can mean lower liquidity, wider price swings and less regulatory oversight—factors investors watch because they affect ease of trading and risk level.

naloxone medical

"Making Life-Saving Naloxone More Accessible for Everyday Preparedness"

Naloxone is a fast-acting medication that temporarily reverses the life-threatening effects of opioid overdose by blocking opioids’ effects on the brain, like an emergency master key that unlocks someone from a dangerous drug-induced shutdown. It matters to investors because demand, pricing, regulatory approvals, product formulations (injectable, nasal spray), and government purchasing programs can drive sales, affect company valuations, and influence litigation and public-health-related revenue streams.

opioid overdose medical

"effective way to reverse opioid overdoses, and today, new solutions like..."

An opioid overdose occurs when a person takes more of an opioid drug than their body can handle, causing dangerously slow or stopped breathing, loss of consciousness, and possible death; it can result from prescription painkillers, illegal opioids, or mixing with other sedatives. Investors should care because overdose trends drive regulatory action, litigation, demand for antidotes and safer therapies, and can materially affect sales, costs, reputations and underwriting risks for drugmakers, hospitals, insurers and others — like a safety failure that reshapes a company’s financial outlook.

blister packaging technical

"contains two doses of NARCAN Nasal Spray within their original blister packaging..."

Blister packaging is a type of product packaging that seals individual doses—such as pills or small consumer items—in pre-formed plastic pockets backed by foil or paper, like eggs in a carton. It protects products from moisture and tampering, makes dosing and inventory easier, and helps meet safety and labeling rules. For investors, blister packaging influences manufacturing cost, shelf life, regulatory compliance and supply-chain efficiency, all of which affect margins and product reliability.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Since the U.S. prescription launch of NARCAN® Nasal Spray in 2016, the medicine has been trusted as a safe, effective way to reverse opioid overdoses, and today, new solutions like the NARCAN® carrying case aims to make accessibility paramount - ‘Trusted Then. Trusted Now’
  
  

GAITHERSBURG, Md., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for over-the-counter (OTC) NARCAN® Nasal Spray to be packaged in a new carrying case, which includes two blister packs, each enclosed with Quick Start Guide. This new packaging option is designed to be easy to carry, compact, discreet and durable, with the goal of integrating seamlessly into daily life to help encourage individuals to have life-saving NARCAN® Nasal Spray readily available during an opioid emergency.

Consumer insights reinforce the critical need for this solution. A recent survey by Emergent indicated that 74 percent of consumers prefer a discreet carrying case over standard packaging. Among college students — a population identified as one of the highest-risk groups for opioid misuse — this preference rises to 81 percent, highlighting the demand for solutions that align with their lifestyle and increase the likelihood of carrying naloxone.¹

“Every second counts in an opioid emergency, and our mission at Emergent is to ensure that life-saving tools like OTC NARCAN® Nasal Spray are readily available, easily accessible and are second nature to carry,” said Paul Williams, senior vice president, head of products business, global government and public affairs at Emergent. “In response to the ongoing opioid overdose epidemic, we believe this new carrying case is an additional option for our customers and consumers to acquire, while encouraging preparedness and expanding accessibility to help save lives.”

During an opioid overdose emergency, OTC NARCAN® Nasal Spray can help save lives. However, everyday carry of the medication remains low, with only 10 percent of the general consumer population carrying it. ² The NARCAN® Nasal Spray carrying case contains two doses of NARCAN® Nasal Spray within their original blister packaging, to help ensure reliability and readiness. Its design prioritizes discretion and portability, helping to reduce the stigma often associated with carrying naloxone and potentially increasing the chances of its use in emergencies. The NARCAN® carrying case will be made available soon to purchase for consumers nationwide at select retailers and online, as well as public interest customers through NARCANDirect®, Emergent’s proprietary ordering and distribution platform.

Since the prescription launch of NARCAN® Nasal Spray in 2016, more than 85 million doses have been distributed across the U.S. and Canada. Visit NARCAN.com and ReadytoRescue.com to learn more.

About NARCAN^® Nasal Spray
NARCAN^® Naloxone HCl Nasal Spray 4 mg is the first FDA-approved, over-the-counter (OTC) 4 mg naloxone product for the emergency treatment of opioid overdose. NARCAN^® Nasal Spray is not a substitute for emergency medical care. Repeat dosing may be necessary. Use as directed.

About Emergent BioSolutions 
At Emergent, our mission is to protect and save lives. For over 25 years, we have prepared those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify. 

Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are forward-looking statements. We generally identify forward-looking statements by using words like "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "future," "goal," "intend," "may," "plan," "position," "possible," "potential," "predict," "project," "should," "target," "will," "would," and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statement will be accurate. Readers should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events or circumstances.  

There are a number of important factors that could cause the company's actual results to differ materially from those indicated by any forward-looking statements. Readers should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the U.S. Securities and Exchange Commission, when evaluating our forward-looking statements.

Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com

Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com

¹ Emergent BioSolutions. Consumer Research for NARCAN® Nasal Spray Carrying Case (509 adults online in Q3 2025). Data on file.
² Jacobson M, Powell D. Naloxone Knowledge, Carrying, Purchase, and Use. JAMA Network Open. 2025;8(3):e2462698. doi:10.1001/jamanetworkopen.2024.62698.
³ Centers for Disease Control and Prevention. Preventing an Opioid Overdose Know the Signs Save a Life. https://www.cdc.gov/drugoverdose/pdf/patients/Preventing-an-Opioid-Overdose-Tip-Card-a.pdf.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Emergent BioSolutions (EBS) announce on January 14, 2026 about NARCAN packaging?

The company announced FDA approval of an sNDA to offer OTC NARCAN nasal spray packaged in a new compact carrying case holding two blistered doses and a Quick Start Guide.

How could the new NARCAN carrying case affect everyday preparedness for opioid overdoses (EBS)?

The case is designed for discretion and portability to encourage daily carry, addressing low current carry rates (reported at 10%) and potentially improving readiness.

When and where will the NARCAN carrying case be available to consumers (EBS)?

The carrying case will be made available soon at select retailers, online, and to public interest customers via NARCANDirect.

What consumer data did Emergent cite about demand for a discreet NARCAN carrying case (EBS)?

Emergent cited a company survey showing 74% overall preference for a discreet carrying case and 81% preference among college students.

How many NARCAN doses has Emergent distributed since the 2016 launch (EBS)?

The company reports more than 85 million doses distributed across the U.S. and Canada since 2016.